Physician profile
Joel Feinstein
NPI 1245262963
$1,587.66
in general payments reported to CMS, 2019-2025
15 companies · $443 in 2025
The $443 reported for 2025 was more than what 77% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $155 · 2020: $132 · 2021: $51.33 · 2022: $171 · 2023: $213 · 2024: $423 · 2025: $443.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,079.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,078.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $363.26 | 2019-2023 | Rebyota, Clenpiq |
| Pfizer INC. | $334.17 | 2023-2025 | |
| Genzyme Corporation | $131.43 | 2023-2024 | |
| Phathom Pharmaceuticals, INC. | $122.73 | 2024-2025 | Voquezna |
| Janssen Biotech, INC. | $122.38 | 2024-2025 | Tremfya, Stelara, Simponi Aria |
| Regeneron Healthcare Solutions, INC. | $78.49 | 2023-2025 | Dupixent |
| Abbvie INC. | $77.54 | 2019-2025 | |
| Cumberland Pharmaceuticals, INC. | $66.56 | 2022-2023 | Kristalose |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $64.80 | 2019-2022 | |
| Micro-Tech Endoscopy USA, INC. | $64.21 | 2022 | |
| Merck Sharp & Dohme LLC | $42.15 | 2023-2024 | Dificid |
| Alnylam Pharmaceuticals INC. | $38.68 | 2025 | Givlaari |
| Takeda Pharmaceuticals U.S.A., INC. | $34.74 | 2019 | |
| Ardelyx, INC. | $24.13 | 2025 | Ibsrela |
| Qol Medical, LLC | $22.39 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Feinstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.